^
    Back
    Association details:
    Biomarker:JAK3 mutation
    Cancer:Prolymphocytic Leukemia
    Drug:Venclexta (venetoclax) (Bcl2 inhibitor) +
    Jakafi (ruxolitinib) (JAK2 inhibitor, JAK1 inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    Blood
    Title:

    BH3 profiling identifies ruxolitinib as a promising partner for venetoclax to treat T-cell prolymphocytic leukemia

    Published date:
    02/17/2021
    Excerpt:
    Based on these results, we treated two patients with refractory T-PLL with the combination of venetoclax and ruxolitinib. We observed a deep response in the JAK3-mutated T-PLL and a stabilization of the unmutated disease.
    DOI:
    10.1182/blood.2020007303